Patent

Anaqua Enhances AcclaimIP Patent Search with AI-Powered Capabilities

Retrieved on: 
Monday, April 8, 2024
Patent, Risk, Intellectual property, Online shopping

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Anaqua , the leading provider of innovation and intellectual property (IP) management technology, continues to enhance its powerful patent search platform, AcclaimIP , setting a new standard in patent search capabilities.

Key Points: 
  • BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Anaqua , the leading provider of innovation and intellectual property (IP) management technology, continues to enhance its powerful patent search platform, AcclaimIP , setting a new standard in patent search capabilities.
  • With a focus on empowering patent searchers with unparalleled control and assistance, AcclaimIP Patent Search offers access to a vast global patent database comprising over 100 million patents worldwide.
  • Designed to cater to the diverse needs of IP professionals, AcclaimIP Patent Search boasts a user-friendly interface that enhances the search experience, facilitating efficient exploration of results and swift discovery of relevant information.
  • One of the most significant features of AcclaimIP Patent Search is its cutting-edge AI Patent Summaries tool.

Sustainable Green Team, Ltd.'s (SGTM) Bold Breakthrough, Revolutionizing Agriculture with Organic Pellet Fertilizer and Micro Encapsulation Technology

Retrieved on: 
Monday, April 8, 2024
Health, Farmer, Nutrient, Environment, Agriculture, Incidence, Green Team, Management, Carbon, OTCQX, IP, Water, Immune system, Patent, Intellectual property, Soil

With the agreement, SGTM can create pelletized organic fertilizers for easier handling and distribution.

Key Points: 
  • With the agreement, SGTM can create pelletized organic fertilizers for easier handling and distribution.
  • Additionally, the deal includes a method to encapsulate beneficial microbes, improving their effectiveness in the soil.
  • This combination has the potential to revolutionize agriculture, providing sustainable agricultural solutions and enhancing soil qualities for farmers.
  • The organic fertilizer developed by SGTM has proven to be a game-changer in the field.

Auddia Announces Issuance of Core AI Patent

Retrieved on: 
Monday, April 8, 2024
Algorithm, Patent, AI, B2C, LLM, CO, Machine learning, AM/FM, Mobile phone

BOULDER, CO, April 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) ("Auddia" or the "Company"), developer of a proprietary AI platform for audio and innovative technologies for podcasts that is reinventing how consumers engage with audio, today announced the U.S. Patent and Trademark Office (USPTO) awarded Auddia with U.S. Patent 11,935,520 for the core AI technology Auddia uses in its flagship faidr app to deliver ad-free AM/FM radio stations to paid subscribers.

Key Points: 
  • BOULDER, CO, April 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) ("Auddia" or the "Company"), developer of a proprietary AI platform for audio and innovative technologies for podcasts that is reinventing how consumers engage with audio, today announced the U.S. Patent and Trademark Office (USPTO) awarded Auddia with U.S. Patent 11,935,520 for the core AI technology Auddia uses in its flagship faidr app to deliver ad-free AM/FM radio stations to paid subscribers.
  • “Issuance of this patent validates our innovation and secures our AI for Audio technology as a proprietary platform we look forward to building upon to drive new innovations in support of additional industry first premium audio listening experiences.”
    In addition to issuance of Patent 11,935,520, the Company has taken the next step in advancing the provisional patent application it filed last year related to leveraging AI to improve large language model (LLM) prompts and the domain specific knowledge of proprietary GPTs.
  • This conversion initiates the process for the patent office to review the application as the next step in pursuing patent protection.
  • Second, the patent covers capturing the AI generated prompt improvements and the enriched outputs of the LLMs to create new GPTs with industry specific domain expertise.

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

Retrieved on: 
Monday, April 8, 2024
Cell, Environment, Human body, Patient, DSM-IV codes, Patent, PLUR

Pluri’s proprietary 3D cell expansion technology mimics the natural lymph node like environment that immune cells have within the human body.

Key Points: 
  • Pluri’s proprietary 3D cell expansion technology mimics the natural lymph node like environment that immune cells have within the human body.
  • The tightly controlled and fully automated bioreactor system provides cells with the conditions they need in order to expand, enabling efficient expansion of immune cells at scale and quality.
  • Pluri's patented technology marks an important milestone in the field of allogeneic cell therapy, positioning the Company at the forefront of innovation.
  • “Pluri’s patented technology represents a significant leap forward in the field of immune cell expansion, addressing the growing global demand for advanced cell-based therapies.

SIRONA BIOCHEM Corporate Update April 2024

Retrieved on: 
Monday, April 8, 2024
AGM, Investment, OTC, Massage, Patent, Marketing, Pharmaceutical industry

VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp .

Key Points: 
  • VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp .
  • (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) provides the following update:
    We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem’s path forward.
  • Instead of dropping the financing share price we are in discussion with investment funds to assist with our financial needs.
  • Sirona Biochem is currently honing its focus on the cosmetic and therapeutic skincare sector, where we identify the most significant commercial potential.

Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology

Retrieved on: 
Monday, April 8, 2024
Aviation, Disease, Patent, SAN, GI, Gastrointestinal tract, Therapy, Stomach, Delivery, Pharmaceutical industry

(Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine.

Key Points: 
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine.
  • The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.
  • 11,938,295 entitled, “Ingestible Device for Delivery of Therapeutic Agent to the Gastrointestinal Tract.” The issued claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal (GI) tract, including the stomach or small intestine.
  • “This latest patent further secures Biora’s broad and comprehensive ownership of liquid jet delivery to the GI tract.

NeuroVigil, World’s Most Valuable Neurotech, Launches iBrain™ in US

Retrieved on: 
Friday, April 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Silicon, Patent, VCS, Division

The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.

Key Points: 
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • A joint abstract by Dr. Low and Dr. Hawking featuring Dr. Hawking’s brain patterns analyzed by NeuroVigil’s technology was released as early as 2012.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

CORRECTION -- NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US

Retrieved on: 
Friday, April 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Patent, VCS, Division

“Who needs implants when you have the real deal?” said Dr. Philip Low, PhD, NeuroVigil’s Chairman, Chief Executive and Technology Officer, Founder and Supermajority Owner.

Key Points: 
  • “Who needs implants when you have the real deal?” said Dr. Philip Low, PhD, NeuroVigil’s Chairman, Chief Executive and Technology Officer, Founder and Supermajority Owner.
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US

Retrieved on: 
Friday, April 5, 2024
Head, Roche, MIT Technology Review, IP, FCCP, Clinic, Seed, Consciousness, Partnership, Novartis, SAN, DNA, Aneurysm, Critical care, Stanford School, Cedars-Sinai Medical Center, Lawyer, Harvard Medical School, DSS, University, MD, Hospital, FDA, Apnea, Brain, ALS, MIT, Neocortex, Biomarker, Bird, Doctor of Philosophy, Human, Brain tumor, BCIS, Silicon, Patent, VCS, Division

The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.

Key Points: 
  • The investigators will initially not be allowed to modify anyone’s therapy based on iBrain data.
  • A joint abstract by Dr. Low and Dr. Hawking featuring Dr. Hawking’s brain patterns analyzed by NeuroVigil’s technology was released as early as 2012.
  • The technology was also successfully demonstrated on ALS sufferer Augie Nieto in 2013 who spelled “COMMUNICATE” with his mind.
  • In the past two years, NeuroVigil has recruited talent from Amgen, Roche, Novartis and MIT in preparation for the launch.

LIS Technologies Inc. Establishes Corporate Affiliation with the Nuclear Institute

Retrieved on: 
Friday, April 5, 2024
Uranium, Nuclear, Isotope, Environment, Patent, Science, Engineering, Society, LIS, Science Council, Nuclear Institute, Engineering Council, Bangladesh Technical Education Board, Renewable energy

“It is a pleasure to count ourselves amongst the Nuclear Institute’s Corporate Affiliates,” said Christo Liebenberg, Chief Executive Officer of LIS Technologies Inc. “The Nuclear Institute has long worked towards the advancement of the nuclear industry and the associated technologies.

Key Points: 
  • “It is a pleasure to count ourselves amongst the Nuclear Institute’s Corporate Affiliates,” said Christo Liebenberg, Chief Executive Officer of LIS Technologies Inc. “The Nuclear Institute has long worked towards the advancement of the nuclear industry and the associated technologies.
  • Additionally, through its numerous events, seminars, and volunteer-led activities, the Nuclear Institute ensures a robust platform for professional interaction and development within the nuclear sector.
  • “We are delighted to welcome LIS Technologies Inc as a Corporate Affiliate of the Nuclear Institute,” said Sarah Beacock, Chief Executive Officer of the Nuclear Institute.
  • “As a proprietary developer of patented advanced laser technology based in the US, LIS Technologies are showing their commitment to advancing nuclear science and technology.